Nicox Sa EUR Ord (NICXF) 12.8500 $NICXF
U.S. FDA grants Priority Review for Nicox's AC-170 New Drug Application
GlobeNewswire - Tue Jun 21, 1:30AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for AC-170, a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016. Such date is indicative and contingent upon the information (including data) to be eventually provided by Nicox in the review period.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.04 (-0.05), CBMG: 14.30 (-0.85), OCAT: 8.47 (+0.01), ZBH: 118.59 (+0.94), PFE: 34.75 (+0.25), LLY: 72.57 (-0.71), GSK: 41.65 (+0.16), GLPG: 52.31 (-0.75), AXSM: 6.68 (+0.51), OMER: 10.87 (-0.01), CANF: 2.81 (+0.14), AST: 2.85 (-0.07), AKTX: 14.00 (-0.61)
Nicox submits New Drug Application for AC-170 to U.S. FDA
GlobeNewswire - Tue Apr 19, 12:40PM CDT
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the submission, through its American subsidiary Nicox Ophthalmics, Inc., of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AC-170, its novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. Based on clinical pediatric data generated with AC-170, the Company also requested a Priority Review, which, if obtained, could result in an FDA decision by the end of 2016 based on PDUFA (Prescription Drug User Fee Act) performance goals.
Nicox to present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 1:40 pm Eastern Time. The conference is being held at The Westin NY Grand Central Hotel in New York City.
Nicox to present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 3:04AM CST
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 231.55 (-3.71), EYEG: 2.98 (-0.13), OHRP: 2.68 (-0.08), AAVL: 4.14 (-0.18)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.21 (-0.07), GALT: 1.41 (+0.03), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), GLPG: 52.31 (-0.75), GILD: 81.79 (-1.20), IBIO: 0.65 (-0.05), TEVA: 50.98 (-0.99), FGEN: 15.68 (-0.27), CELGZ: 1.44 (-0.01)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.75 (+0.25), AMPE: 3.33 (+0.11), DYAX: 38.04 (-0.37), AGN: 231.55 (-3.71), EYEG: 2.98 (-0.13), AAVL: 4.14 (-0.18), OHRP: 2.68 (-0.08), REGN: 345.14 (-7.52)
Nicox completes reverse stock split and provides business update
GlobeNewswire - Thu Dec 03, 12:34AM CST
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of its reverse stock split and provided an update regarding ongoing corporate initiatives and activities.
Nicox and Fera Pharmaceuticals sign exclusive license agreement for naproxcinod in the U.S.
GlobeNewswire - Tue Nov 10, 12:35AM CST
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, and Fera Pharmaceuticals, a privately-held specialty pharmaceutical company, announced today that they have entered into an exclusive license agreement for the development and commercialization of Nicox's naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate, in the United States.
Nicox announces reverse stock split
GlobeNewswire - Mon Oct 19, 12:35AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that its Board of Directors is implementing a 5-for-1 reverse stock split, as approved by Nicox's shareholders at the October 13, 2015 Extraordinary General Meeting. The reverse stock split will become effective on December 3, 2015.
Nicox to present at the 14th Annual BIO Investor Forum
GlobeNewswire - Tue Oct 13, 3:03AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 14 Annual BIO Investor Forum in San Francisco on Tuesday October 20, 2015, at 10:00 am Pacific Time.
Blepharitis Pipeline Review, H2 2015 - Reviews Key Players Involved in the Therapeutics Development for Blepharitis
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cb3rdq/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned - Allergan Plc - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. For more information visit http://www.researchandmarkets.com/research/cb...lepharitis
AGN: 231.55 (-3.71), FOMX: 6.05 (+0.07)
Global Gastric Injury Clinical Trials Review, H1, 2015 - Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4kkzf/gastric_injury) has announced the addition of the "Gastric Injury Global Clinical Trials Review, H1, 2015" report to their offering. Gastric Injury Global Clinical Trials Review, H1, 2015 provides data on the Gastric Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastric Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastric Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Yuhan Corporation - NicOx S.A. - Pozen, Inc. - Pfizer Inc. - Dong-A Socio Holdings Co. Ltd. - Actavis plc Clinical Trial Overview of Top Institutes / Government - The University of Tokyo Hospital - Yokohama City University - Aichi Gakuin University - Alexandria University - Chinese University of Hong Kong - Committee on Chinese Medicine and Pharmacy - Hokkaido University Hospital - Hoshigaoka Koseinenkin Hospital - Hyogo College Of Medicine - Jichi Medical University For more information visit http://www.researchandmarkets.com/research/q4...ric_injury
PFE: 34.75 (+0.25), POZN: 5.94 (-0.43)
NICOX : Bausch + Lomb confirms submission of Vesneo(TM) NDA to US FDA
GlobeNewswire - Fri Jul 24, 12:43AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today noted the confirmation by Valeant Pharmaceuticals International, Inc's. (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb,that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for VESNEO(TM) (latanoprostene bunod ophthalmic solution 0.024%), an IOP lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension.
Retinal Vein Occlusion - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ws2jkc/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Allergan, Inc. - Avalanche Biotechnologies, Inc. - F. Hoffmann-La Roche Ltd. - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/ws...tinal_vein
AGN: 231.55 (-3.71), OHRP: 2.68 (-0.08), AAVL: 4.14 (-0.18), REGN: 345.14 (-7.52)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 1.89 (-0.11), PFE: 34.75 (+0.25), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), GLPG: 52.31 (-0.75), IDRA: 1.53 (-0.07), SHPG: 174.62 (-1.01), SRPT: 17.05 (-0.80), RTRX: 18.09 (+0.54), PTCT: 6.72 (-0.26), SMMT: 7.95 (+0.18), XLRN: 33.73 (-1.14)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 231.55 (-3.71), OHRP: 2.68 (-0.08), CLTX: 36.01 (+16.34), XNCR: 13.70 (-0.56), OCUL: 5.38 (-0.07)
Global Ocular Pain Therapeutics Pipeline Review, H1 2015 - 8 Companies & 11 Drug Profiles
M2 - Fri Jun 05, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72mmmt/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Auven Therapeutics Management L.L.L.P - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. Drug Profiles - fluticasone propionate - ISV-303 - ketorolac tromethamine - loteprednol etabonate - loteprednol etabonate next generation - mapracorat - NT-71 - NT-72 - RTA-408 - RX-10045 - SYL-1001 For more information visit http://www.researchandmarkets.com/research/72...cular_pain
VRX.TO: 27.70 (-1.07), PTIE: 2.07 (-0.01)
InSite Vision Reports First Quarter 2015 Financial Results
BusinessWire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
U.S. FDA grants Priority Review for Nicox's AC-170 New Drug Application
GlobeNewswire - Tue Jun 21, 1:30AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for AC-170, a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016. Such date is indicative and contingent upon the information (including data) to be eventually provided by Nicox in the review period.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.04 (-0.05), CBMG: 14.30 (-0.85), OCAT: 8.47 (+0.01), ZBH: 118.59 (+0.94), PFE: 34.75 (+0.25), LLY: 72.57 (-0.71), GSK: 41.65 (+0.16), GLPG: 52.31 (-0.75), AXSM: 6.68 (+0.51), OMER: 10.87 (-0.01), CANF: 2.81 (+0.14), AST: 2.85 (-0.07), AKTX: 14.00 (-0.61)
Nicox submits New Drug Application for AC-170 to U.S. FDA
GlobeNewswire - Tue Apr 19, 12:40PM CDT
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the submission, through its American subsidiary Nicox Ophthalmics, Inc., of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AC-170, its novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. Based on clinical pediatric data generated with AC-170, the Company also requested a Priority Review, which, if obtained, could result in an FDA decision by the end of 2016 based on PDUFA (Prescription Drug User Fee Act) performance goals.
Nicox to present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 1:40 pm Eastern Time. The conference is being held at The Westin NY Grand Central Hotel in New York City.
Nicox to present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 3:04AM CST
Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 231.55 (-3.71), EYEG: 2.98 (-0.13), OHRP: 2.68 (-0.08), AAVL: 4.14 (-0.18)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.21 (-0.07), GALT: 1.41 (+0.03), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), GLPG: 52.31 (-0.75), GILD: 81.79 (-1.20), IBIO: 0.65 (-0.05), TEVA: 50.98 (-0.99), FGEN: 15.68 (-0.27), CELGZ: 1.44 (-0.01)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.75 (+0.25), AMPE: 3.33 (+0.11), DYAX: 38.04 (-0.37), AGN: 231.55 (-3.71), EYEG: 2.98 (-0.13), AAVL: 4.14 (-0.18), OHRP: 2.68 (-0.08), REGN: 345.14 (-7.52)
Nicox completes reverse stock split and provides business update
GlobeNewswire - Thu Dec 03, 12:34AM CST
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of its reverse stock split and provided an update regarding ongoing corporate initiatives and activities.
Nicox and Fera Pharmaceuticals sign exclusive license agreement for naproxcinod in the U.S.
GlobeNewswire - Tue Nov 10, 12:35AM CST
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, and Fera Pharmaceuticals, a privately-held specialty pharmaceutical company, announced today that they have entered into an exclusive license agreement for the development and commercialization of Nicox's naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate, in the United States.
Nicox announces reverse stock split
GlobeNewswire - Mon Oct 19, 12:35AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that its Board of Directors is implementing a 5-for-1 reverse stock split, as approved by Nicox's shareholders at the October 13, 2015 Extraordinary General Meeting. The reverse stock split will become effective on December 3, 2015.
Nicox to present at the 14th Annual BIO Investor Forum
GlobeNewswire - Tue Oct 13, 3:03AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 14 Annual BIO Investor Forum in San Francisco on Tuesday October 20, 2015, at 10:00 am Pacific Time.
Blepharitis Pipeline Review, H2 2015 - Reviews Key Players Involved in the Therapeutics Development for Blepharitis
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cb3rdq/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned - Allergan Plc - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. For more information visit http://www.researchandmarkets.com/research/cb...lepharitis
AGN: 231.55 (-3.71), FOMX: 6.05 (+0.07)
Global Gastric Injury Clinical Trials Review, H1, 2015 - Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4kkzf/gastric_injury) has announced the addition of the "Gastric Injury Global Clinical Trials Review, H1, 2015" report to their offering. Gastric Injury Global Clinical Trials Review, H1, 2015 provides data on the Gastric Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastric Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastric Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Yuhan Corporation - NicOx S.A. - Pozen, Inc. - Pfizer Inc. - Dong-A Socio Holdings Co. Ltd. - Actavis plc Clinical Trial Overview of Top Institutes / Government - The University of Tokyo Hospital - Yokohama City University - Aichi Gakuin University - Alexandria University - Chinese University of Hong Kong - Committee on Chinese Medicine and Pharmacy - Hokkaido University Hospital - Hoshigaoka Koseinenkin Hospital - Hyogo College Of Medicine - Jichi Medical University For more information visit http://www.researchandmarkets.com/research/q4...ric_injury
PFE: 34.75 (+0.25), POZN: 5.94 (-0.43)
NICOX : Bausch + Lomb confirms submission of Vesneo(TM) NDA to US FDA
GlobeNewswire - Fri Jul 24, 12:43AM CDT
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today noted the confirmation by Valeant Pharmaceuticals International, Inc's. (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb,that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for VESNEO(TM) (latanoprostene bunod ophthalmic solution 0.024%), an IOP lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension.
Retinal Vein Occlusion - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ws2jkc/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Allergan, Inc. - Avalanche Biotechnologies, Inc. - F. Hoffmann-La Roche Ltd. - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/ws...tinal_vein
AGN: 231.55 (-3.71), OHRP: 2.68 (-0.08), AAVL: 4.14 (-0.18), REGN: 345.14 (-7.52)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 1.89 (-0.11), PFE: 34.75 (+0.25), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), GLPG: 52.31 (-0.75), IDRA: 1.53 (-0.07), SHPG: 174.62 (-1.01), SRPT: 17.05 (-0.80), RTRX: 18.09 (+0.54), PTCT: 6.72 (-0.26), SMMT: 7.95 (+0.18), XLRN: 33.73 (-1.14)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 231.55 (-3.71), OHRP: 2.68 (-0.08), CLTX: 36.01 (+16.34), XNCR: 13.70 (-0.56), OCUL: 5.38 (-0.07)
Global Ocular Pain Therapeutics Pipeline Review, H1 2015 - 8 Companies & 11 Drug Profiles
M2 - Fri Jun 05, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72mmmt/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Auven Therapeutics Management L.L.L.P - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. Drug Profiles - fluticasone propionate - ISV-303 - ketorolac tromethamine - loteprednol etabonate - loteprednol etabonate next generation - mapracorat - NT-71 - NT-72 - RTA-408 - RX-10045 - SYL-1001 For more information visit http://www.researchandmarkets.com/research/72...cular_pain
VRX.TO: 27.70 (-1.07), PTIE: 2.07 (-0.01)
InSite Vision Reports First Quarter 2015 Financial Results
BusinessWire - Tue May 12, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended March 31, 2015. Revenues for the quarter ended March 31, 2015 were $3.4 million compared to $1.2 million for the same period in 2014; increase in revenues was due to a $3.0 million upfront license payment. Net loss for the quarter ended March 31, 2015 was $0.8 million, or $0.01 per share, compared to a net loss of $4.7 million, or $0.04 per share, in 2014. As of March 31, 2015, cash and cash equivalents totaled $1.1 million.
